Virtus LifeSci Biotech Clinical Trials ETF (BBC) Declines 1.56% for May 17

May 17 is a negative day so far for Virtus LifeSci Biotech Clinical Trials ETF (NASDAQ:BBC) as the ETF is active during the day after losing 1.56% to hit $27.75 per share. The exchange traded fund has 27.80M net assets and 2.44% volatility this month.

Over the course of the day 981 shares traded hands, as compared to an average volume of 7,940 over the last 30 days for Virtus LifeSci Biotech Clinical Trials ETF (NASDAQ:BBC).

The ETF is -22.58% of its 52-Week High and 37.30% of its low, and is currently having ATR of 0.71. This year’s performance is 19.51% while this quarter’s performance is 7.18%.

The ETF’s YTD performance is 19.52%, the 1 year is -10.61% and the 3 year is 12.39%.

The ETF’s average P/E ratio is 7.55, the price to book is 3.21, the price to sales is 4.39 and the price to cashflow is 7.01. It was started on 12/17/2014. The fund’s top holdings are: Nightstar Therapeutics PLC ADR for 2.19% of assets, Epizyme Inc for 2.03%, Insmed Inc for 1.96%, Voyager Therapeutics Inc for 1.95%, uniQure NV for 1.93%, Arqule Inc for 1.71%, Ascendis Pharma A/S ADR for 1.70%, Eidos Therapeutics Inc for 1.66%, Sage Therapeutics Inc for 1.60%, Biohaven Pharmaceutical Holding Co Ltd for 1.59%. The ETF sector weights are: Basic Materials 1.06%, CONSUMER_CYCLICAL 0.00%, Financial Services 0.00%, Realestate 0.00%, Consumer Defensive 0.00%, Healthcare 98.94%, Utilities 0.00%, Communication Services 0.00%, Energy 0.00%, Industrials 0.00%, Technology 0.00%. The ETF currently as yield.

More notable recent Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC) news were published by: Seekingalpha.com which released: “Brexit Deadlock And Investor Uncertainty – Seeking Alpha” on May 07, 2019, also Investorplace.com with their article: “5 Safe and Sound ETF Strategies for 2H – Investorplace.com” published on July 12, 2018, Seekingalpha.com published: “Weekly Commentary: Officially On ‘Periphery’ Contagion Watch – Seeking Alpha” on April 27, 2019. More interesting news about Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC) were released by: Seekingalpha.com and their article: “Try This ETF Pair To Round Out Your Biotech Exposure – Seeking Alpha” published on March 15, 2018 as well as Seekingalpha.com‘s news article titled: “U.K. asks for short Brexit delay; EU suggests longer one – Seeking Alpha” with publication date: April 05, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.